Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Definium Therapeutics, Inc. (DFTX)
USD43.65
-3.42 (-7.27%)
US NASDAQ Healthcare Biotechnology
Address
One World Trade Center 10007
New York, NY, US
New York, NY, US
CEO
Robert Barrow
Website
definiumtx.com
IPO
2016-11-15
CIK 1813814 ISIN CA24477V1058
Also trades on
CBOE CA · MMED.NE (CAD)
NASDAQ Capital Market · MNMD (USD)
NASDAQ Global Select · DFTX (USD)
Other OTC · MMCWF (USD)
Other OTC · MMDCF (USD)
Description
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD43.65
-3.42 (-7.27%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
2.21
Float Shares
93.69M
Free Float %
85.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.12% | -7.44% | -4.90% | +34.35% | +81.94% | +58.03% | +232.18% | +569.62% | -52.82% | +526.04% | +526.04% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
43.65
Low
25.00
-42.7%
Consensus
35.50
-18.7%
Median
36.50
-16.4%
High
48.00
+10.0%
DCF (Unlevered)
2.83
-93.5%
DCF (Levered)
2.89
-93.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 12 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 4 |
39.25
-10.1%
|
| Last Quarter | 5 |
36.40
-16.6%
|
| Last Year | 9 |
34.78
-20.3%
|
| All Time | 14 |
27.86
-36.2%
|
Quality scores
Altman Z-Score
8.33
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-1,273.3% Q1'26: -102.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +250.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-87.3% ★ Q1'26: +24.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 EPS Ana. |
Dec 2027 8 Rev. Ana. 10 EPS Ana. |
Dec 2028 13 Rev. Ana. 12 EPS Ana. |
Dec 2029 12 Rev. Ana. 10 EPS Ana. |
Dec 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 1.50M (-100.0%)
|
—
— – —
-100.0% YoY
|
47.38M
47.38M – 47.38M
|
205.27M
200.86M – 209.67M
+333.2% YoY
|
496.47M
496.47M – 496.47M
+141.9% YoY
|
839.95M
839.95M – 839.95M
+69.2% YoY
|
| EBITDA |
-105.87M
|
-178.31M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-106.40M
|
-178.31M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-108.68M
est: -1.01B (+89.2%)
|
-183.79M
est: -183.79M (+0.0%)
|
-194.75M
-206.73M – -182.76M
-6.0% YoY
|
-152.70M
-187.13M – -118.27M
+21.6% YoY
|
-77.70M
-187.99M – 293.26M
+49.1% YoY
|
86.17M
86.17M – 86.17M
+210.9% YoY
|
266.33M
266.33M – 266.33M
+209.1% YoY
|
| SGA |
38.62M
|
48.64M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.54
est: -1.43 (-7.6%)
|
-2.06
est: -2.00 (-2.9%)
|
-2.20
-2.31 – -2.05
-10.0% YoY
|
-1.67
-2.09 – -1.32
+24.2% YoY
|
-0.68
-2.10 – 3.28
+59.5% YoY
|
0.96
0.96 – 0.96
+242.9% YoY
|
2.98
2.98 – 2.98
+209.1% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-22 | Leerink Partners | Outperform | Outperform | Maintain |
| 2026-04-16 | Canaccord Genuity | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
48
Total invested
47.99M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
48
+40 vs prev Q
New positions
46
Closed positions
6
Increased
46
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | CANDRIAM S.C.A. | 1.29M +1.3M (+100.0%) | 24.45M +24.4M (+100.0%) | 1.45% +1.448 pp | 0.13% +0.127 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 2 | BANK OF NEW YORK MELLON CORP | 752.9K +752.9K (+100.0%) | 14.23M +14.2M (+100.0%) | 0.84% +0.843 pp | 0.00% +0.003 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 3 | NUVEEN, LLC | 698.1K +698.1K (+100.0%) | 13.19M +13.2M (+100.0%) | 0.78% +0.782 pp | 0.00% +0.004 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 4 | UBS GROUP AG | 494.0K +494.0K (+100.0%) | 9.34M +9.3M (+100.0%) | 0.55% +0.553 pp | 0.00% +0.001 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 5 | DEUTSCHE BANK AG\ | 411.8K +411.8K (+100.0%) | 7.78M +7.8M (+100.0%) | 0.46% +0.461 pp | 0.00% +0.003 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 6 | SEVEN GRAND MANAGERS, LLC | 225.0K +225.0K (+100.0%) | 4.25M +4.3M (+100.0%) | 0.25% +0.252 pp | 0.28% +0.284 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 7 | SWISS NATIONAL BANK | 158.4K +158.4K (+100.0%) | 2.99M +3.0M (+100.0%) | 0.18% +0.177 pp | 0.00% +0.002 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 8 | ADVISORSHARES INVESTMENTS LLC | 91.3K +91.3K (+100.0%) | 1.73M +1.7M (+100.0%) | 0.10% +0.102 pp | 0.31% +0.315 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 9 | LPL FINANCIAL LLC | 78.3K +78.3K (+100.0%) | 1.48M +1.5M (+100.0%) | 0.09% +0.088 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 10 | KESTRA PRIVATE WEALTH SERVICES, LLC | 50.6K +50.6K (+100.0%) | 956.1K +956.1K (+100.0%) | 0.06% +0.057 pp | 0.01% +0.012 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 11 | NISA INVESTMENT ADVISORS, LLC | 48.9K +48.9K (+100.0%) | 924.3K +924.3K (+100.0%) | 0.05% +0.055 pp | 0.00% +0.003 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 12 | CENTERBOOK PARTNERS LP | 42.8K +42.8K (+100.0%) | 809.5K +809.5K (+100.0%) | 0.05% +0.048 pp | 0.04% +0.044 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 13 | JENNISON ASSOCIATES LLC | 40.0K +40.0K (+100.0%) | 755.2K +755.2K (+100.0%) | 0.04% +0.045 pp | 0.00% +0.001 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 14 | — | 34.8K +34.8K (+100.0%) | 657.7K +657.7K (+100.0%) | 0.04% +0.039 pp | 0.47% +0.465 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 15 | NEW YORK STATE COMMON RETIREMENT FUND | 29.6K +29.6K (+100.0%) | 559.4K +559.4K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.001 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 16 | STATE OF NEW JERSEY COMMON PENSION FUND D | 27.4K +27.4K (+100.0%) | 518.6K +518.6K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.002 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 17 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 27.4K +27.4K (+100.0%) | 517.1K +517.1K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.004 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 18 | KINGSWOOD WEALTH ADVISORS, LLC | 26.6K +26.6K (+100.0%) | 502.6K +502.6K (+100.0%) | 0.03% +0.030 pp | 0.02% +0.024 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 19 | BAY RIVERS GROUP | 26.3K +26.3K (+100.0%) | 497.9K +497.9K (+100.0%) | 0.03% +0.030 pp | 0.21% +0.207 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 20 | ARIZONA STATE RETIREMENT SYSTEM | 22.1K +22.1K (+100.0%) | 416.8K +416.8K (+100.0%) | 0.02% +0.025 pp | 0.00% +0.002 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 21 | CONCURRENT INVESTMENT ADVISORS, LLC | 21.3K +21.3K (+100.0%) | 402.3K +402.3K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.004 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 22 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 20.2K +20.2K (+100.0%) | 381.6K +381.6K (+100.0%) | 0.02% +0.023 pp | 0.03% +0.029 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 23 | STRS OHIO | 19.3K +19.3K (+100.0%) | 364.8K +364.8K (+100.0%) | 0.02% +0.022 pp | 0.00% +0.001 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 24 | PROSHARE ADVISORS LLC | 18.7K +18.7K (+100.0%) | 354.0K +354.0K (+100.0%) | 0.02% +0.021 pp | 0.00% +0.001 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 25 | HIGHTOWER ADVISORS, LLC | 18.6K +18.6K (+100.0%) | 350.8K +350.8K (+100.0%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 26 | SEQUOIA FINANCIAL ADVISORS, LLC | 17.2K +17.2K (+100.0%) | 325.9K +325.9K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.002 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 27 | PROFUND ADVISORS LLC | 14.2K +14.2K (+100.0%) | 268.3K +268.3K (+100.0%) | 0.02% +0.016 pp | 0.01% +0.010 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 28 | PICTET ASSET MANAGEMENT HOLDING SA | 13.3K +13.3K (+100.0%) | 251.3K +251.3K (+100.0%) | 0.01% +0.015 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 29 | MONEY CONCEPTS CAPITAL CORP | 13.0K +13.0K (+100.0%) | 245.7K +245.7K (+100.0%) | 0.01% +0.015 pp | 0.01% +0.014 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 30 | TWELVE POINTS WEALTH MANAGEMENT LLC | 12.2K +12.2K (+100.0%) | 231.4K +231.4K (+100.0%) | 0.01% +0.014 pp | 0.05% +0.051 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 31 | DIVERSIFY WEALTH MANAGEMENT, LLC | 11.0K +11.0K (+100.0%) | 225.4K +225.4K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.004 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 32 | SANCTUARY ADVISORS, LLC | 11.5K +11.5K (+100.0%) | 216.7K +216.7K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.001 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 33 | CHICAGO PARTNERS INVESTMENT GROUP LLC | 9.3K +9.3K (+100.0%) | 214.8K +214.8K (+100.0%) | 0.01% +0.010 pp | 0.00% +0.005 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 34 | RPS ADVISORY SOLUTIONS LLC | 11.4K +11.4K (+100.0%) | 214.6K +214.6K (+100.0%) | 0.01% +0.013 pp | 0.12% +0.122 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 35 | SG AMERICAS SECURITIES, LLC | 10.5K +10.5K (+100.0%) | 198.0K +198.0K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 36 | TEACHER RETIREMENT SYSTEM OF TEXAS | 10.3K +10.3K (+100.0%) | 194.7K +194.7K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.001 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 37 | COMMONWEALTH EQUITY SERVICES, LLC | 10.3K +10.3K (+100.0%) | 193.7K +193.7K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 38 | KING WEALTH | 10.0K +10.0K (+100.0%) | 189.0K +189.0K (+100.0%) | 0.01% +0.011 pp | 0.02% +0.024 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 39 | SHARPEPOINT LLC | 10.0K +10.0K (+100.0%) | 189.0K +189.0K (+100.0%) | 0.01% +0.011 pp | 0.11% +0.113 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 40 | NORTH STAR INVESTMENT MANAGEMENT CORP. | 7.6K +7.6K (+100.0%) | 143.1K +143.1K (+100.0%) | 0.01% +0.009 pp | 0.01% +0.009 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 41 | HOLLENCREST CAPITAL MANAGEMENT | 7.4K +7.4K (+100.0%) | 139.6K +139.6K (+100.0%) | 0.01% +0.008 pp | 0.01% +0.005 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 42 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 5.2K +5.2K (+100.0%) | 98.3K +98.3K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 43 | SOUND INCOME STRATEGIES, LLC | 3.7K +— (+0.0%) | 76.0K +20.5K (+36.9%) | 0.00% +0.000 pp | 0.00% +0.001 pp | USD13.39 +41.2% | 2 qtrs — |
| 44 | FIFTH THIRD BANCORP | 3.3K +3.3K (+100.0%) | 62.4K +62.4K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 45 | STERLING CAPITAL MANAGEMENT LLC | 2.4K +2.4K (+100.0%) | 46.2K +46.2K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.001 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 46 | GF FUND MANAGEMENT CO. LTD. | 2.2K +2.2K (+100.0%) | 41.8K +41.8K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.001 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 47 | KBC GROUP NV | 2.2K +2.2K (+100.0%) | 41.0K +41.0K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 48 | CREWE ADVISORS LLC | 2.0K +2.0K (+100.0%) | 37.8K +37.8K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.003 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 49 | GAMMA INVESTING LLC | 1.1K +1.1K (+100.0%) | 21.0K +21.0K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.001 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 50 | OPAL WEALTH ADVISORS, LLC | 1.1K +1.1K (+100.0%) | 20.8K +20.8K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.005 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 51 | STONE HOUSE INVESTMENT MANAGEMENT, LLC | 1.0K +1.0K (+100.0%) | 18.9K +18.9K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.003 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 52 | FIRST HORIZON CORP | 962.00 +962.0 (+100.0%) | 18.2K +18.2K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.001 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 53 | FARTHER FINANCE ADVISORS, LLC | 567.00 +567.0 (+100.0%) | 11.7K +11.7K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 54 | MASSMUTUAL TRUST CO FSB/ADV | 568.00 +568.0 (+100.0%) | 10.7K +10.7K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 55 | PRIVATE WEALTH MANAGEMENT GROUP, LLC | 450.00 +450.0 (+100.0%) | 8.5K +8.5K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.002 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 56 | NVWM, LLC | 416.00 +416.0 (+100.0%) | 7.9K +7.9K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.002 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 57 | MEEDER ASSET MANAGEMENT INC | 353.00 +353.0 (+100.0%) | 6.7K +6.7K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 58 | WESTERN PACIFIC WEALTH MANAGEMENT, LP | 333.00 +333.0 (+100.0%) | 6.3K +6.3K (+100.0%) | 0.00% +0.000 pp | 0.01% +0.006 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 59 | ROTHSCHILD INVESTMENT LLC | 292.00 +292.0 (+100.0%) | 5.5K +5.5K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 60 | PARALLEL ADVISORS, LLC | 232.00 +232.0 (+100.0%) | 4.4K +4.4K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 61 | ATLANTIC EDGE PRIVATE WEALTH MANAGEMENT, LLC | 193.00 +193.0 (+100.0%) | 3.6K +3.6K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.001 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 62 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 155.00 +155.0 (+100.0%) | 2.9K +2.9K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 63 | SALEM INVESTMENT COUNSELORS INC | 150.00 +150.0 (+100.0%) | 2.8K +2.8K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 64 | HIGHMARK WEALTH MANAGEMENT LLC | 100.00 +100.0 (+100.0%) | 1.9K +1.9K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.001 pp | USD18.89 +0.1% | 1 qtrs NEW |
| 65 | NBC SECURITIES, INC. | 100.00 +100.0 (+100.0%) | 1.9K +1.9K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.89 +0.1% | 1 qtrs NEW |
| 66 | SBI SECURITIES CO., LTD. | 98.00 +98.0 (+100.0%) | 1.9K +1.9K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.90 +0.0% | 1 qtrs NEW |
| 67 | KOHMANN BOSSHARD FINANCIAL SERVICES, LLC | 66.00 +66.0 (+100.0%) | 1.2K +1.2K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.89 +0.1% | 1 qtrs NEW |
| 68 | ACTIVEST WEALTH MANAGEMENT | 66.00 +66.0 (+100.0%) | 1.2K +1.2K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.89 +0.1% | 1 qtrs NEW |
| 69 | LOUISBOURG INVESTMENTS INC. | 52.00 +52.0 (+100.0%) | 983.00 +983.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.88 +0.1% | 1 qtrs NEW |
| 70 | PLANTE MORAN FINANCIAL ADVISORS, LLC | 36.00 +36.0 (+100.0%) | 680.00 +680.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.89 +0.1% | 1 qtrs NEW |
| 71 | ROBBINS FARLEY | 28.00 +28.0 (+100.0%) | 530.00 +530.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.89 +0.1% | 1 qtrs NEW |
| 72 | CORECAP ADVISORS, LLC | 5.00 +5.0 (+100.0%) | 95.00 +95.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.80 +0.5% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.00
Bullish
Ratio by volume
3.00
Bullish
Buys
6
Sells
3
Shares acquired
910.0K
Shares disposed
43.2K
Cash buys
—
Cash sales
3.00
Net activity
+866,849
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-25 | Sullivan Mark | Officer | S-Sale | D | Common Shares | 10,702 | 18.47 | 197.7K | 271,079 | D | ↗ |
| 2026-03-25 | Karlin Daniel | Officer | S-Sale | D | Common Shares | 8,018 | 18.47 | 148.1K | 413,317 | D | ↗ |
| 2026-03-25 | Barrow Robert | Director / Officer | S-Sale | D | Common Shares | 24,431 | 18.47 | 451.2K | 752,454 | D | ↗ |
| 2026-02-03 | Wiley Matthew T. | Officer | A-Award | A | Common Shares | 115,000 | 0.00 | — | 115,000 | D | ↗ |
| 2026-02-03 | Sullivan Mark | Officer | A-Award | A | Common Shares | 125,000 | 0.00 | — | 407,576 | D | ↗ |
| 2026-02-03 | Roberts Brandi | Officer | A-Award | A | Common Shares | 150,000 | 0.00 | — | 150,000 | D | ↗ |
| 2026-02-03 | Karlin Daniel | Officer | A-Award | A | Common Shares | 150,000 | 0.00 | — | 575,025 | D | ↗ |
| 2026-02-03 | Barrow Robert | Director / Officer | A-Award | A | Common Shares | 320,000 | 0.00 | — | 1,098,477 | D | ↗ |
| 2026-01-29 | Adsett Roger | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 17.24 | 862.0K | 50,000 | D | ↗ |
| 2025-12-26 | Sullivan Mark | Officer | S-Sale | D | Common Shares | 11,276 | 13.15 | 148.2K | 282,576 | D | ↗ |
| 2025-12-26 | Karlin Daniel | Officer | S-Sale | D | Common Shares | 5,600 | 13.15 | 73.6K | 425,025 | D | ↗ |
| 2025-12-26 | Barrow Robert | Director / Officer | S-Sale | D | Common Shares | 25,791 | 13.15 | 339.1K | 778,477 | D | ↗ |
| 2025-09-25 | Sullivan Mark | Officer | S-Sale | D | Common Shares | 11,278 | 9.77 | 110.2K | 293,852 | D | ↗ |
| 2025-09-25 | Karlin Daniel | Officer | S-Sale | D | Common Shares | 7,704 | 9.77 | 75.3K | 430,625 | D | ↗ |
| 2025-09-25 | Barrow Robert | Director / Officer | S-Sale | D | Common Shares | 25,797 | 9.77 | 252.0K | 804,268 | D | ↗ |
| 2025-06-25 | Sullivan Mark | Officer | S-Sale | D | Common Shares | 11,491 | 6.80 | 78.1K | 305,130 | D | ↗ |
| 2025-06-25 | Karlin Daniel | Officer | S-Sale | D | Common Shares | 7,848 | 6.80 | 53.4K | 438,329 | D | ↗ |
| 2025-06-25 | Barrow Robert | Director / Officer | S-Sale | D | Common Shares | 26,491 | 6.80 | 180.1K | 830,065 | D | ↗ |
| 2025-06-12 | Vallone Carol A | Director | A-Award | A | Stock Option (Right to Buy) | 75,187 | 7.30 | 548.9K | 75,187 | D | ↗ |
| 2025-06-12 | Krebs Andreas | Director | A-Award | A | Stock Option (Right to Buy) | 75,187 | 7.30 | 548.9K | 75,187 | D | ↗ |
| 2025-06-12 | GRYSKA DAVID W | Director | A-Award | A | Stock Option (Right to Buy) | 75,187 | 7.30 | 548.9K | 75,187 | D | ↗ |
| 2025-06-12 | CRYSTAL ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 75,187 | 7.30 | 548.9K | 75,187 | D | ↗ |
| 2025-06-12 | Bruhn Suzanne Louise | Director | A-Award | A | Stock Option (Right to Buy) | 75,187 | 7.30 | 548.9K | 75,187 | D | ↗ |
| 2025-06-02 | Roberts Brandi | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 7.26 | 3.63M | 500,000 | D | ↗ |
| 2025-03-25 | Sullivan Mark | Officer | S-Sale | D | Common Shares | 6,576 | 6.74 | 44.3K | 316,621 | D | ↗ |
| 2025-03-25 | Liao Carrie | Officer | S-Sale | D | Common Shares | 2,347 | 6.74 | 15.8K | 144,923 | D | ↗ |
| 2025-03-25 | Karlin Daniel | Officer | S-Sale | D | Common Shares | 6,836 | 6.74 | 46.1K | 446,177 | D | ↗ |
| 2025-03-25 | Barrow Robert | Director / Officer | S-Sale | D | Common Shares | 21,208 | 6.74 | 142.9K | 856,556 | D | ↗ |
| 2025-03-17 | Wiley Matthew T. | Officer | A-Award | A | Stock Option (Right to Buy) | 350,000 | 6.35 | 2.22M | 350,000 | D | ↗ |
| 2025-03-12 | Sullivan Mark | Officer | A-Award | A | Common Shares | 150,000 | 0.00 | — | 323,197 | D | ↗ |
| 2025-03-12 | Liao Carrie | Officer | A-Award | A | Common Shares | 50,000 | 0.00 | — | 142,270 | D | ↗ |
| 2025-03-12 | Karlin Daniel | Officer | A-Award | A | Common Shares | 115,000 | 0.00 | — | 453,013 | D | ↗ |
| 2025-03-12 | Barrow Robert | Director / Officer | A-Award | A | Common Shares | 350,000 | 0.00 | — | 877,764 | D | ↗ |
| 2024-12-26 | Sullivan Mark | Officer | S-Sale | D | Common Shares | 4,519 | 7.43 | 33.6K | 173,197 | D | ↗ |
| 2024-12-26 | Liao Carrie | Officer | S-Sale | D | Common Shares | 2,273 | 7.43 | 16.9K | 97,270 | D | ↗ |
| 2024-12-26 | Karlin Dan | Officer | S-Sale | D | Common Shares | 6,643 | 7.43 | 49.4K | 338,013 | D | ↗ |
| 2024-12-26 | Barrow Robert | Director / Officer | S-Sale | D | Common Shares | 19,106 | 7.43 | 142.0K | 526,666 | D | ↗ |
| 2024-12-05 | GRYSKA DAVID W | Director | P-Purchase | A | Common Shares | 2,500 | 7.17 | 17.9K | 19,851 | D | ↗ |
| 2024-09-25 | Sullivan Mark | Officer | S-Sale | D | Common Shares | 4,430 | 5.98 | 26.5K | 177,716 | D | ↗ |
| 2024-09-25 | Liao Carrie | Officer | S-Sale | D | Common Shares | 2,352 | 5.98 | 14.1K | 99,543 | D | ↗ |
| 2024-09-25 | Karlin Dan | Officer | S-Sale | D | Common Shares | 6,871 | 5.98 | 41.1K | 344,656 | D | ↗ |
| 2024-09-25 | Barrow Robert | Director / Officer | S-Sale | D | Common Shares | 19,771 | 5.98 | 118.2K | 545,772 | D | ↗ |
| 2024-08-23 | GRYSKA DAVID W | Director | P-Purchase | A | Common Shares | 3,500 | 5.98 | 20.9K | 17,351 | — | ↗ |
| 2024-08-21 | Halperin Wernli Miri | Officer | M-Exempt | D | Stock Option (Right to Buy) | 50,000 | 3.70 | 185.0K | 0 | — | ↗ |
| 2024-08-20 | Barrow Robert | Director / Officer | P-Purchase | A | Common Shares | 500 | 6.12 | 3.1K | 565,543 | — | ↗ |
| 2024-08-19 | Barrow Robert | Director / Officer | P-Purchase | A | Common Shares | 500 | 6.31 | 3.2K | 565,043 | — | ↗ |
| 2024-06-25 | Sullivan Mark | Officer | S-Sale | D | Common Shares | 17,854 | 7.22 | 128.9K | 182,146 | — | ↗ |
| 2024-06-25 | Karlin Dan | Officer | S-Sale | D | Common Shares | 6,925 | 7.22 | 50.0K | 351,527 | — | ↗ |
| 2024-06-25 | Barrow Robert | Director / Officer | S-Sale | D | Common Shares | 15,659 | 7.22 | 113.1K | 564,543 | — | ↗ |
| 2024-06-10 | Vallone Carol A | Director | A-Award | A | Stock Option (Right to Buy) | 16,506 | 7.25 | 119.7K | 16,506 | — | ↗ |
| 2024-06-10 | Krebs Andreas | Director | A-Award | A | Stock Option (Right to Buy) | 16,506 | 7.25 | 119.7K | 16,506 | — | ↗ |
| 2024-06-10 | GRYSKA DAVID W | Director | A-Award | A | Stock Option (Right to Buy) | 16,506 | 7.25 | 119.7K | 16,506 | — | ↗ |
| 2024-06-10 | CRYSTAL ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 16,506 | 7.25 | 119.7K | 16,506 | — | ↗ |
| 2024-06-10 | Bruhn Suzanne Louise | Director | A-Award | A | Stock Option (Right to Buy) | 16,506 | 7.25 | 119.7K | 16,506 | — | ↗ |
| 2024-03-25 | Karlin Dan | Officer | S-Sale | D | Common Shares | 6,578 | 9.50 | 62.5K | 358,452 | — | ↗ |
| 2024-03-25 | Greenway Schond L. | Officer | F-InKind | D | Common Shares | 5,560 | 9.78 | 54.4K | 211,057 | — | ↗ |
| 2024-03-25 | Barrow Robert | Director / Officer | S-Sale | D | Common Shares | 16,519 | 9.50 | 156.9K | 580,202 | — | ↗ |
| 2024-02-27 | Wernli Miri Halperin | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 4.98 | 622.5K | 125,000 | — | ↗ |
| 2024-02-27 | Sullivan Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 4.98 | 622.5K | 125,000 | — | ↗ |
| 2024-02-27 | Liao Carrie | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 4.98 | 498.0K | 100,000 | — | ↗ |
| 2024-02-27 | Karlin Dan | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 4.98 | 747.0K | 150,000 | — | ↗ |
| 2024-02-27 | Greenway Schond L. | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 4.98 | 747.0K | 150,000 | — | ↗ |
| 2024-02-27 | Barrow Robert | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 4.98 | 1.99M | 400,000 | — | ↗ |
| 2023-12-26 | Karlin Dan | Officer | S-Sale | D | Common Shares | 6,774 | 3.63 | 24.6K | 365,030 | — | ↗ |
| 2023-12-26 | Greenway Schond L. | Officer | S-Sale | D | Common Shares | 5,652 | 3.63 | 20.5K | 216,617 | — | ↗ |
| 2023-12-26 | Barrow Robert | Director / Officer | S-Sale | D | Common Shares | 13,237 | 3.63 | 48.1K | 596,721 | — | ↗ |
| 2023-09-25 | Karlin Dan | Officer | S-Sale | D | Common Shares | 3,240 | 3.58 | 11.6K | 371,804 | — | ↗ |
| 2023-09-25 | Greenway Schond L. | Officer | S-Sale | D | Common Shares | 3,854 | 3.58 | 13.8K | 222,269 | — | ↗ |
| 2023-09-25 | Barrow Robert | Director / Officer | S-Sale | D | Common Shares | 5,268 | 3.57 | 18.8K | 619,960 | — | ↗ |
| 2023-08-25 | Greenway Schond L. | Officer | S-Sale | D | Common Shares | 20,000 | 3.80 | 76.0K | 228,031 | — | ↗ |
| 2023-06-27 | Karlin Dan | Officer | S-Sale | D | Common Shares | 3,820 | 3.19 | 12.2K | 381,685 | — | ↗ |
| 2023-06-27 | Greenway Schond L. | Officer | S-Sale | D | Common Shares | 7,694 | 3.19 | 24.5K | 251,972 | — | ↗ |
| 2023-06-27 | Barrow Robert | Director / Officer | S-Sale | D | Common Shares | 7,086 | 3.19 | 22.6K | 631,873 | — | ↗ |
| 2023-06-21 | Vallone Carol A | Director | A-Award | A | Common Shares | 13,671 | 0.00 | — | 16,544 | — | ↗ |
| 2023-06-21 | Krebs Andreas | Director | A-Award | A | Stock Option (Right to Buy) | 19,203 | 3.61 | 69.3K | 29,748 | — | ↗ |
| 2023-06-21 | GRYSKA DAVID W | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-21 | CRYSTAL ROGER | Director | A-Award | A | Common Shares | 13,671 | 0.00 | — | 19,623 | — | ↗ |
| 2023-06-21 | Bruhn Suzanne Louise | Director | A-Award | A | Common Shares | 13,671 | 0.00 | — | 19,623 | — | ↗ |
| 2023-04-13 | Sullivan Mark | Officer | A-Award | A | Common Shares | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2023-03-14 | Wernli Miri Halperin | Director / Officer | A-Award | A | Common Shares | 100,000 | 0.00 | — | 185,000 | — | ↗ |
| 2023-03-14 | Liao Carrie | Officer | A-Award | A | Common Shares | 75,000 | 0.00 | — | 478,430 | — | ↗ |
| 2023-03-14 | Karlin Dan | Officer | A-Award | A | Common Shares | 125,000 | 0.00 | — | 385,505 | — | ↗ |
| 2023-03-14 | Greenway Schond L. | Officer | A-Award | A | Common Shares | 175,000 | 0.00 | — | 259,666 | — | ↗ |
| 2023-03-14 | Barrow Robert | Director / Officer | A-Award | A | Common Shares | 400,000 | 0.00 | — | 638,959 | — | ↗ |
| 2023-03-01 | Karlin Dan | Officer | S-Sale | D | Common Shares | 3,577 | 3.51 | 12.6K | 260,505 | — | ↗ |
| 2023-03-01 | Barrow Robert | Director / Officer | S-Sale | D | Common Shares | 8,273 | 3.51 | 29.0K | 238,959 | — | ↗ |
| 2022-12-21 | Karlin Dan | Officer | S-Sale | D | Common Shares | 1,211 | 2.69 | 3.3K | 264,082 | — | ↗ |
| 2022-12-21 | Barrow Robert | Officer | S-Sale | D | Common Shares | 3,861 | 2.69 | 10.4K | 247,232 | — | ↗ |
| 2022-10-27 | Karlin Dan | Officer | S-Sale | D | Common Shares | 644 | 3.00 | 1.9K | 265,293 | — | ↗ |
| 2022-10-25 | Karlin Dan | Officer | S-Sale | D | Common Shares | 541 | 2.81 | 1.5K | 265,937 | — | ↗ |
| 2022-10-25 | Barrow Robert | Officer | S-Sale | D | Common Shares | 1,207 | 2.81 | 3.4K | 251,093 | — | ↗ |
| 2022-10-18 | Barrow Robert | Officer | S-Sale | D | Common Shares | 1,220 | 3.11 | 3.8K | 252,300 | — | ↗ |
| 2022-09-27 | Karlin Dan | Officer | S-Sale | D | Common Shares | 640 | 5.87 | 3.8K | 266,478 | — | ↗ |
| 2022-09-26 | Karlin Dan | Officer | S-Sale | D | Common Shares | 565 | 5.51 | 3.1K | 267,118 | — | ↗ |
| 2022-09-26 | Barrow Robert | Director / Officer | S-Sale | D | Common Shares | 1,264 | 5.51 | 7.0K | 253,520 | — | ↗ |
| 2022-09-16 | Barrow Robert | Director / Officer | S-Sale | D | Common Shares | 1,350 | 7.26 | 9.8K | 254,784 | — | ↗ |
| 2022-08-31 | Karlin Dan | Officer | S-Sale | D | Common Shares | 1,204 | 11.67 | 14.1K | 267,683 | — | ↗ |
| 2022-08-31 | Barrow Robert | Officer | S-Sale | D | Common Shares | 1,228 | 11.67 | 14.3K | 256,134 | — | ↗ |
| 2022-08-16 | Barrow Robert | Officer | S-Sale | D | Common Shares | 20,350 | 0.68 | 13.8K | 3,860,438 | — | ↗ |
| 2022-08-11 | CRYSTAL ROGER | Director | A-Award | A | Director's Deferred Share Units | 503,773 | 0.00 | — | 503,773 | — | ↗ |
| 2022-08-11 | Bruhn Suzanne Louise | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-07-25 | Karlin Dan | Officer | S-Sale | D | Common Shares | 8,361 | 0.69 | 5.8K | 4,043,120 | — | ↗ |
| 2022-07-25 | Barrow Robert | Officer | S-Sale | D | Common Shares | 18,681 | 0.69 | 12.9K | 3,880,788 | — | ↗ |
| 2022-07-18 | Barrow Robert | Officer | S-Sale | D | Common Shares | 19,388 | 0.70 | 13.6K | 3,899,469 | — | ↗ |
| 2022-06-27 | Karlin Dan | Officer | S-Sale | D | Common Shares | 26,238 | 0.70 | 18.4K | 4,051,481 | — | ↗ |
| 2022-06-27 | Barrow Robert | Officer | S-Sale | D | Common Shares | 36,762 | 0.70 | 25.7K | 3,918,857 | — | ↗ |
| 2022-06-16 | Barrow Robert | Officer | S-Sale | D | Common Shares | 21,275 | 0.70 | 14.9K | 3,955,619 | — | ↗ |
| 2022-06-01 | Vallone Carol A | Director | A-Award | A | Stock Option (Right to Buy) | 133,744 | 0.00 | — | 161,587 | — | ↗ |
| 2022-06-01 | Makes Brigid | Director | A-Award | A | Director's Deferred Share Units | 361,680 | 0.00 | — | 643,804 | — | ↗ |
| 2022-06-01 | Krebs Andreas | Director | A-Award | A | Subordinate Voting Shares | 21,552 | 0.00 | — | 21,552 | — | ↗ |
| 2022-05-27 | Karlin Dan | Officer | S-Sale | D | Subordinate Voting Shares | 9,555 | 0.82 | 7.8K | 4,077,719 | — | ↗ |
| 2022-05-25 | Karlin Dan | Officer | S-Sale | D | Subordinate Voting Shares | 8,242 | 0.77 | 6.3K | 4,087,274 | — | ↗ |
| 2022-05-25 | Barrow Robert | Officer | S-Sale | D | Subordinate Voting Shares | 18,415 | 0.77 | 14.2K | 3,976,894 | — | ↗ |
| 2022-05-23 | Greenway Schond L. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-05-18 | Barrow Robert | Director / Officer | S-Sale | D | Subordinate Voting Shares | 18,948 | 0.71 | 13.5K | 3,995,309 | — | ↗ |
| 2022-05-15 | Barrow Robert | Officer | F-InKind | D | Subordinate Voting Shares | 18,948 | 0.82 | 15.5K | 3,995,309 | — | ↗ |
| 2022-05-11 | Makes Brigid | Director | J-Other | A | Subordinate Voting Shares | 67,678 | 0.00 | — | 94,050 | — | ↗ |
| 2022-04-26 | Karlin Dan | Officer | F-InKind | D | Subordinate Voting Shares | 13,038 | 0.81 | 10.6K | 4,095,516 | — | ↗ |
| 2022-04-18 | Barrow Robert | Officer | F-InKind | D | Subordinate Voting Shares | 19,110 | 0.92 | 17.6K | 4,014,257 | — | ↗ |
| 2022-03-28 | Karlin Dan | Officer | F-InKind | D | Subordinate Voting Shares | 10,203 | 1.17 | 11.9K | 4,108,554 | — | ↗ |
| 2022-03-24 | Wernli Miri Halperin | Officer | A-Award | A | Subordinate Voting Shares | 600,000 | 0.00 | — | 1,275,000 | — | ↗ |
| 2022-03-24 | Karlin Dan | Officer | A-Award | A | Subordinate Voting Shares | 950,000 | 0.00 | — | 4,118,757 | — | ↗ |
| 2022-03-24 | Hu Cynthia W. | Officer | A-Award | A | Stock Option (Right to Buy) | 1,560,000 | 0.00 | — | 1,560,000 | — | ↗ |
| 2022-03-24 | Barrow Robert | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 2,910,000 | 1.18 | 3.43M | 6,425,500 | — | ↗ |
| 2022-03-15 | Barrow Robert | Officer | F-InKind | D | Subordinate Voting Shares | 12,612 | 1.00 | 12.6K | 2,213,367 | — | ↗ |
| 2022-02-26 | Karlin Dan | Officer | F-InKind | D | Subordinate Voting Shares | 118,143 | 1.21 | 143.0K | 3,168,757 | — | ↗ |
| 2022-02-15 | Barrow Robert | Director / Officer | F-InKind | D | Subordinate Voting Shares | 18,734 | 1.35 | 25.3K | 2,225,979 | — | ↗ |
| 2022-02-10 | Liao Carrie | Officer | A-Award | A | Subordinate Voting Shares | 403,430 | 0.00 | — | 403,430 | — | ↗ |
| 2022-01-15 | Barrow Robert | Director / Officer | F-InKind | D | Subordinate Voting Shares | 190,287 | 1.05 | 199.8K | 2,244,713 | — | ↗ |
| 2022-01-05 | Hurst Stephen L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-01 | Wernli Miri Halperin | Director / Officer | — | D | Stock Option (Right to Buy) | 682,500 | 2.42 | 1.65M | 0 | — | ↗ |
| 2022-01-01 | Vinson Sarah Y | Director | — | D | Directors' Deferred Share Units | 19,141 | 0.00 | — | 0 | — | ↗ |
| 2022-01-01 | Vallone Carol A | Director | — | D | Stock Option (Right to Buy) | 16,295 | 2.38 | 38.8K | 0 | — | ↗ |
| 2022-01-01 | Makes Brigid | Director | — | D | Directors' Deferred Share Units | 37,758 | 0.00 | — | 0 | — | ↗ |
| 2022-01-01 | Liao Carrie | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-01 | Krebs Andreas | Director | — | D | Directors' Deferred Share Units | 17,322 | 0.00 | — | 0 | — | ↗ |
| 2022-01-01 | Karlin Dan | Officer | — | D | Stock Option (Right to Buy) | 1,469,000 | 2.42 | 3.55M | 0 | — | ↗ |
| 2022-01-01 | Hurst Stephen L | Director | — | I | Subordinate Voting Shares | 0 | 0.00 | — | 39,000,000 | — | ↗ |
| 2022-01-01 | Hu Cynthia W. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-01 | Barrow Robert | Director / Officer | — | D | Subordinate Voting Shares | 0 | 0.00 | — | 2,435,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
109.07M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Robert Barrow Chief Executive Officer | 655.0K | — | 11.72M | — | 378.3K | 14.4K | 12.77M | 91.79% | ↗ |
| 2 | 2025 | Brandi L. Roberts Chief Financial Officer | 288.8K | — | 1.82M | 2.89M | 121.3K | 401.00 | 5.12M | 91.98% | ↗ |
| 3 | 2025 | Daniel Karlin, M.D. Chief Medical Officer | 510.0K | — | 3.26M | — | 214.2K | 14.5K | 4.00M | 81.54% | ↗ |
| 4 | 2024 | Robert Barrow Chief Executive Officer | 623.5K | — | — | 1.67M | 359.2K | 14.3K | 2.67M | 62.64% | ↗ |
| 5 | 2024 | Daniel Karlin, M.D. Chief Medical Officer | 485.5K | — | — | 627.0K | 203.4K | 14.4K | 1.33M | 47.13% | ↗ |
| 6 | 2024 | Schond Greenway Former Chief Financial Officer | 152.9K | — | — | 701.0K | — | 342.3K | 1.20M | 58.60% | ↗ |
| 7 | 2024 | Mark Sullivan, J.D. Chief Legal Officer | 439.8K | — | — | 522.5K | 184.3K | 14.6K | 1.16M | 45.00% | ↗ |
| 8 | 2023 | Robert Barrow Chief Executive Officer | 598.8K | — | 1.21M | — | 318.7K | 13.7K | 2.14M | 56.55% | ↗ |
| 9 | 2023 | Schond Greenway Chief Financial Officer | 430.0K | — | 530.3K | — | 167.2K | 11.4K | 1.14M | 46.56% | ↗ |
| 10 | 2023 | Schond Greenway Former Chief Financial Officer | 430.0K | — | 530.3K | — | 167.2K | 11.4K | 1.14M | 46.56% | ↗ |
| 11 | 2023 | Mark Sullivan, J.D. Chief Legal Officer | 308.2K | — | 596.0K | — | 163.4K | 12.8K | 1.08M | 55.17% | ↗ |
| 12 | 2023 | Daniel Karlin, M.D. Chief Medical Officer | 462.5K | — | 378.8K | — | 180.5K | 15.5K | 1.04M | 36.51% | ↗ |
| 13 | 2022 | Robert Barrow Chief Executive Officer | 671.6K | — | 2.07M | 2.20M | 282.5K | 2.0K | 5.23M | 81.71% | ↗ |
| 14 | 2022 | Daniel Karlin, M.D. Chief Medical Officer | 481.3K | — | 1.08M | 945.4K | 170.0K | 12.4K | 2.69M | 75.33% | ↗ |
| 15 | 2022 | Schond Greenway Chief Financial Officer | 243.1K | — | 976.2K | 828.7K | 97.3K | 2.9K | 2.15M | 84.02% | ↗ |
| 16 | 2021 | JR Rahn Former Chief Executive Officer | 213.3K | — | 8.57M | 4.96M | — | 1.25M | 14.99M | 90.27% | ↗ |
| 17 | 2021 | Robert Barrow Chief Executive Officer | 350.0K | 358.4K | 5.80M | 5.38M | — | — | 11.89M | 94.04% | ↗ |
| 18 | 2021 | Dr. Daniel Karlin Chief Medical Officer | 291.7K | 175.0K | 2.47M | 1.97M | — | — | 4.91M | 90.49% | ↗ |
| 19 | 2021 | Dr. Miri Halperin Wernli Executive President | 377.5K | 175.0K | 1.15M | 964.5K | — | — | 2.66M | 79.26% | ↗ |
| 20 | 2021 | Stephen Hurst Former Co-Chief Executive Officer | 118.3K | — | 55.0K | 46.6K | — | 839.4K | 1.06M | 9.59% | ↗ |
| 21 | 2020 | JR Rahn Former Chief Executive Officer | 266.7K | — | — | 967.8K | — | — | 1.23M | 78.40% | ↗ |
| 22 | 2020 | Dr. Miri Halperin Wernli Executive President | 131.3K | 72.9K | — | 791.9K | — | — | 996.1K | 79.50% | ↗ |
| 23 | 2020 | Stephen Hurst Former Co-Chief Executive Officer | 266.7K | 80.0K | — | — | — | — | 346.7K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert Barrow | Chief Executive Officer & Director | 1M | male |
| Daniel Rollings Karlin | Chief Medical Officer | 738.7K | — |
| Mark R. Sullivan | Chief Legal Officer & Corporate Secretary | 638.6K | male |
| Brandi L. Roberts | Chief Financial Officer | 619.2K | female |
| Scott Freeman | Co-Founder & Clinical Advisor | 316.1K | — |
| Peter Mack | Senior Vice President of Pharmaceutical Development & Operations | — | male |
| Beth Calitri | Vice President of Corporate Communications | — | female |
| Stephanie Fagan | Chief Corporate Affairs Officer | — | female |
| Gitanjali Jain | VP & Head of Investor Relations | — | female |
| Gregg Pratt | Chief Regulatory & Quality Assurance Officer | — | — |
| Leonard Latchman | Co-Founder | — | male |
| Matthew Wiley | Chief Commercial Officer | — | male |
ESG Rating
ESG Score History MEDICAL - PHARMACEUTICALS
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DFTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
